Longitudinal evaluation using FP-CIT in patients with parkinsonism
M D Martínez-Valle Torres1, S J Ortega Lozano2, M J Gómez Heredia3
1Servicio de Medicina Nuclear, Hospital Universitario «Virgen de la Victoria», Málaga, España.
Neurologia (Barcelona, Spain)
|October 22, 2013
Summary
Serial FP-CIT scans for parkinsonism are usually not needed, though they may be justified in specific clinical scenarios, particularly when initial results are negative but symptoms progress.
Area of Science:
- Neurology
- Nuclear Medicine
Background:
- Parkinsonism diagnosis can be challenging, with initial imaging sometimes yielding inconclusive results.
- DaTscans (FP-CIT) are used to assess dopaminergic deficits in parkinsonian syndromes.
Purpose of the Study:
- To evaluate the utility of serial FP-CIT (DaTscans) in patients with parkinsonism, focusing on cases with initially negative findings.
- To analyze discrepancies between initial FP-CIT results and clinical progression.
Main Methods:
- Retrospective analysis of 92 parkinsonism patients who underwent two FP-CIT studies.
- Semi-quantitative analysis of clinical history and literature to interpret discrepant results.
Main Results:
- Eleven of 92 patients showed discrepancies between initial and follow-up FP-CIT studies.
- Seven patients initially had normal FP-CIT scans but later showed pathological findings.
- Tremor-dominant parkinsonism was noted in 4 of these 7 cases.
Conclusions:
- Serial FP-CIT (DaTscans) are generally not required for parkinsonism diagnosis.
- Repeat FP-CIT imaging may be beneficial in select clinical situations with evolving symptoms or initial uncertainty.
Related Concept Videos
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34